Tellurium Compound AS101 Induces PC12 Differentiation and Rescues the Neurons from Apoptotic Death
: Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra (SN). Studies show that anti‐apoptotic and neurotrophic agents are suitable candidates to prevent delayed cell death and/or restore neural function. Here we present the nontoxic immunomodulating c...
Saved in:
Published in: | Annals of the New York Academy of Sciences Vol. 1010; no. 1; pp. 659 - 666 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, UK
Blackwell Publishing Ltd
01-12-2003
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | : Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra (SN). Studies show that anti‐apoptotic and neurotrophic agents are suitable candidates to prevent delayed cell death and/or restore neural function. Here we present the nontoxic immunomodulating compound AS101, which has the ability to induce neurite outgrowth and neural differentiation in PC12 cells. The present study shows that components of the ras signaling pathway are crucial for AS101‐induced PC12 differentiation. These include p21ras and its downstream effectors, c‐raf‐1 and MEK, as well as PI3K. Moreover, these components mediate AS101‐induced upregulation of p21waf, which is obligatory for AS101‐induced PC12 differentiation. Furthermore, nitric oxide plays a significant role in these AS101 activities. Finally, we show that AS101 prevents apoptosis of NGF‐differentiated PC12 cells after NGF withdrawal. Taken together, these results suggest that AS101 induces PC12 cell differentiation and survival by activating the ras‐ERK1/2 and ras‐PI3K signal transduction pathways, as well as inducing NO production. Our findings may be important in understanding the regulation of survival/apoptosis of neurons deprived of neurotropic support. Futhermore the data propose that AS101 may have clinical potential in the treatment of neurodegenerative disorders like Parkinson's disease. |
---|---|
Bibliography: | ArticleID:NYAS659 istex:1FD45667A957FEC9F82EDC45FAFA4E065F8DA58D ark:/67375/WNG-QNL65BH7-V ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0077-8923 1749-6632 |
DOI: | 10.1196/annals.1299.120 |